WO2012118308A3 - 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물. - Google Patents

피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물. Download PDF

Info

Publication number
WO2012118308A3
WO2012118308A3 PCT/KR2012/001450 KR2012001450W WO2012118308A3 WO 2012118308 A3 WO2012118308 A3 WO 2012118308A3 KR 2012001450 W KR2012001450 W KR 2012001450W WO 2012118308 A3 WO2012118308 A3 WO 2012118308A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
preventing
cardiovascular diseases
treating cardiovascular
pyrazole derivative
Prior art date
Application number
PCT/KR2012/001450
Other languages
English (en)
French (fr)
Other versions
WO2012118308A2 (ko
WO2012118308A9 (ko
Inventor
배윤수
이기인
이지현
조한중
김진오
Original Assignee
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이화여자대학교 산학협력단 filed Critical 이화여자대학교 산학협력단
Priority to US14/002,103 priority Critical patent/US20140088152A1/en
Publication of WO2012118308A2 publication Critical patent/WO2012118308A2/ko
Publication of WO2012118308A9 publication Critical patent/WO2012118308A9/ko
Publication of WO2012118308A3 publication Critical patent/WO2012118308A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

본 발명은 피라졸 유도체 화합물 및 이의 약제학적으로 허용되는 염을 포함하는 조성물을 제공하며, 상기 조성물은 우수한 심혈관 질환 예방 및 치료효과가 있다.
PCT/KR2012/001450 2011-02-28 2012-02-27 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물. WO2012118308A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/002,103 US20140088152A1 (en) 2011-02-28 2012-02-27 Composition for preventing and treating cardiovascular diseases, containing pyrazole derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110017962 2011-02-28
KR10-2011-0017962 2011-02-28

Publications (3)

Publication Number Publication Date
WO2012118308A2 WO2012118308A2 (ko) 2012-09-07
WO2012118308A9 WO2012118308A9 (ko) 2012-10-26
WO2012118308A3 true WO2012118308A3 (ko) 2012-12-20

Family

ID=46758363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001450 WO2012118308A2 (ko) 2011-02-28 2012-02-27 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물.

Country Status (3)

Country Link
US (1) US20140088152A1 (ko)
KR (1) KR20120098489A (ko)
WO (1) WO2012118308A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101856444B1 (ko) * 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
KR101840702B1 (ko) 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
KR102191180B1 (ko) * 2019-05-31 2020-12-15 삼진제약주식회사 안질환 치료용 조성물
CN113980001B (zh) * 2021-11-10 2024-01-30 贵州医科大学 吡唑醇-哒嗪酮类耦联化合物、其药物组合物及其在药物中的应用
CN115991698B (zh) * 2022-11-03 2024-03-29 广东中科药物研究有限公司 一种杂环化合物及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175176A (en) * 1990-07-24 1992-12-29 Bayer Aktiengesellschaft 1-[pyri(mi)dyl-(2)]-hydroxy-pyrazole microbicides
KR19990036814A (ko) * 1997-10-06 1999-05-25 로버트 흐라이탁, 미쉘 베스트 피라졸 유도체, 이의 제조 방법 및 약제로서의 이의 용도
KR100942382B1 (ko) * 2008-03-25 2010-02-12 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물
KR100987557B1 (ko) * 2008-03-18 2010-10-12 이화여자대학교 산학협력단 혈관 재협착 치료 또는 예방용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175176A (en) * 1990-07-24 1992-12-29 Bayer Aktiengesellschaft 1-[pyri(mi)dyl-(2)]-hydroxy-pyrazole microbicides
KR19990036814A (ko) * 1997-10-06 1999-05-25 로버트 흐라이탁, 미쉘 베스트 피라졸 유도체, 이의 제조 방법 및 약제로서의 이의 용도
KR100987557B1 (ko) * 2008-03-18 2010-10-12 이화여자대학교 산학협력단 혈관 재협착 치료 또는 예방용 조성물
KR100942382B1 (ko) * 2008-03-25 2010-02-12 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물

Also Published As

Publication number Publication date
WO2012118308A2 (ko) 2012-09-07
WO2012118308A9 (ko) 2012-10-26
US20140088152A1 (en) 2014-03-27
KR20120098489A (ko) 2012-09-05

Similar Documents

Publication Publication Date Title
WO2012019426A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2014002051A3 (en) Complement pathway modulators and uses thereof
WO2014002058A3 (en) Complement pathway modulators and uses thereof
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
IN2014KN00948A (ko)
WO2014009833A3 (en) Complement pathway modulators and uses thereof
WO2012019430A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
PL2808325T3 (pl) Podstawione azole, przeciwwirusowy składnik czynny, kompozycja farmaceutyczna, sposób ich wytwarzania i stosowania
WO2012122011A3 (en) Amino-quinolines as kinase inhibitors
WO2013100566A8 (en) Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
WO2010091197A3 (en) Tablets for combination therapy
WO2013009527A3 (en) Factor ixa inhibitors
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
WO2012118308A3 (ko) 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물.
HK1206938A1 (en) Process for the preparation of 3-chloro-4,5,6-trifluoro- picolinonitrile 3--456--
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
AP2012006232A0 (en) New association between 4-ä3-ÄCIS-hexahydrocyclopentaÄcÜpyrrol-2(1H)-YLÜpropoxyübenzamide and an Acetylcholinesterase inhibitor, and pharmaceutical compositions containing it.
WO2012061785A3 (en) Ice inhibiting compounds and uses thereof
WO2012140596A8 (en) Glycoside derivatives and uses thereof
WO2012030170A3 (ko) 카나비노이드 1 수용체 저해제로 작용하는 신규 화합물
WO2012154879A3 (en) Autophagy inhibitors
EP3037091A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
EP3037093A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12752323

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14002103

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12752323

Country of ref document: EP

Kind code of ref document: A2